BRVE

Braveheart Bio, Inc.

NASDAQ· Healthcare· Biotechnology

$27.44-1.51%

Key metrics

Market cap: $1.94B
P/E: —
Forward P/E: —
P/B: —
Dividend yield: —
EPS: -$1.85
ROE: —
Profit margin: 0.00%
Revenue growth: —
Beta: —
52-week high: $32.00
52-week low: $24.61

Investors holding this

Major managers that reported this stock in their latest 13F.

None of the investors we track reported a position in BRVE.

About the company

Braveheart Bio, Inc. a clinical-stage biopharmaceutical company focused on developing therapies for patients with hypertrophic cardiomyopathy (HCM) and other serious cardiovascular diseases. It develops and offers BHB-1893 and HRS-1893, an oral small-molecule cardiac myosin inhibitor (CMI) for the treatment of obstructive HCM and non-obstructive HCM. The company was incorporated in 2024 and is headquartered in San Francisco, California.

Employees: 30
Headquarters: San Francisco, United States
Website: braveheart.bio

Company description provided by Yahoo Finance.